Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis

• Príomhchruthaitheoirí: Alexandrina Balanean (Údar), Cherrishe Brown-Bickerstaff (Údar), Andrew Klink (Údar), Vardhaman Patel (Údar), Hanke Zheng (Údar), Laetitia N'Dri (Údar), Keith Wittstock (Údar), Bruce Feinberg (Údar), Mark Chaballa (Údar), Vadim Khaychuk (Údar), Jill Kaufman (Údar), Prathamesh Pathak (Údar), Gordon Lam (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Becaris Publishing Limited, 2024-11-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Aim: In rheumatoid arthritis (RA), seropositivity for both anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) is associated with disease severity and therapeutic response. Biologic (b) diseasemodifying antirheumatic drugs (DMARDs) such as abatacept are recommended after inadequate...